ethyl pyruvate has been researched along with Cognition Disorders in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bhatt, N; Bittar, A; Gaikwad, S; Garcia, S; Kayed, R; McAllen, S; Montalbano, M; Puangmalai, N; Sengupta, U; Sonawane, M | 1 |
| Fukunaga, K; Haga, H; Han, F; Matsuo, K; Yabuki, Y; Zhang, C | 1 |
2 other study(ies) available for ethyl pyruvate and Cognition Disorders
| Article | Year |
|---|---|
Tau oligomer induced HMGB1 release contributes to cellular senescence and neuropathology linked to Alzheimer's disease and frontotemporal dementia.
Topics: Alzheimer Disease; Animals; Astrocytes; Brain; Cell Nucleus; Cells, Cultured; Cellular Senescence; Cognition Disorders; Frontotemporal Dementia; Glycyrrhizic Acid; HMGB1 Protein; Humans; Mice, Inbred C57BL; Mice, Transgenic; Phenotype; Protein Transport; Pyruvates; tau Proteins | 2021 |
Enhancement of ATP production ameliorates motor and cognitive impairments in a mouse model of MPTP-induced Parkinson's disease.
Topics: Adenosine Triphosphate; Animals; Avoidance Learning; CA1 Region, Hippocampal; Cognition Disorders; Dopamine; Dopaminergic Neurons; Male; Mice; Mice, Inbred C57BL; Neuroprotective Agents; Parkinsonian Disorders; Pars Compacta; Piperazines; Pyruvates; Receptors, sigma; Rotarod Performance Test; Spatial Memory; Substantia Nigra; Ventral Tegmental Area | 2019 |